GSK plc

As of June 30, 2026, GSK plc carries a market capitalization of 92.24B, placing it among publicly traded companies globally. Its enterprise value stands at 109.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

GSK plc's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, GSK plc has 4.01B shares outstanding.

As of June 30, 2026, GSK plc trades at a trailing price-to-earnings ratio of 16.55. The price-to-sales ratio is 2.40, and the price-to-book ratio stands at 4.50.

As of June 30, 2026, GSK plc trades at an EV/EBITDA multiple of 9.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. GSK plc trades at an EV/FCF ratio of 15.83, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 109.26B versus a market cap of 92.24B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GSK plc maintains a current ratio of 0.82, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.18, indicating elevated leverage, while an interest coverage ratio of 13.84 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GSK plc posted a return on equity (ROE) of 29.73, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.88, useful for judging operating efficiency across full business cycles. The company generates approximately 572,783.81 in revenue per employee across its workforce of 67,288.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.47 indicates how many times GSK plc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, GSK plc recorded 744.06M in income tax expense. That works out to an effective tax rate of 10.86, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.85B, leaving 5.60B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, GSK plc's stock has gained approximately 20.54% over the past 52 weeks. The 50-day moving average sits at 21.68, while the 200-day moving average is 22.61.

Over the twelve months ended June 30, 2026, GSK plc generated 38.54B in revenue and converted that into 5.60B in net income, yielding earnings per share of 1.50. EBITDA reached 11.09B, while operating income came in at 7.98B.

As of June 30, 2026, GSK plc holds 3.61B in cash and equivalents against 21.17B in total debt, resulting in a net debt position of -3.60B. Total book value stands at 20.48B, with working capital of -4.61B providing operational flexibility.

GSK plc produced 9.67B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.48B in capital expenditures, free cash flow totaled 6.19B - equivalent to 1.54 per share.

Over the twelve months ended June 30, 2026, GSK plc posted a gross margin of 72.73, reflecting its pricing power and cost economics. The operating margin of 20.70 and net profit margin of 14.52 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, GSK plc paid dividends of 0.77 per share. The dividend payout ratio of 46.73 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to GSK plc shareholders.

GSK plc's most recent stock split took place on July 19, 2022 with a 5:4 split ratio.

As of June 30, 2026, GSK plc has an Altman Z-Score of 2.86, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.